Congresswoman Urges FDA to Ban Zantac, Ranitidine Products

Lawsuit News from OnderLaw

Rosa DeLauro (CT-03)has asked the FDA to remove all ranitidine-based products from shelves.

Friday, January 10, 2020 - ranitidine BanOne congresswoman has led a push to ban Zantac and other ranitidine-based medications in the U.S. due to concerns that they are causing cancer.

Heartburn drug Zantac and other products containing a drug called ranitidine have taken a hit in recent months after online pharmacy Valisure discovered the carcinogen N-nitrosodimethylamine (NDMA) in every ranitidine product it tested in June 2019. NDMA has been linked to digestive tract, kidney, bladder, and other cancers.

The FDA responded three months after it was notified of Valisure's findings by issuing a warning to healthcare providers and to the public about the problem. In the warning, they suggested that more testing was needed.

Since then, several companies, including Zantac manufacturer Sanofi, as well as American Health Packaging, Amneal, Apotex, Appco Pharma, Aurobindo, Denton Pharma, Dr. Reddy's, Glenmark, Golden State Medical Supply, Lannett Company, Novitium Pharma, Perrigo, PrecisionDose, and Sandoz have recalled their ranitidine-based products. Additional recalls continue to be announced.

In a letter to FDA Commissioner Stephen Hahn and HHS Secretary Alex Azar, Congresswoman Rosa DeLauro (CT-03) urged the FDA to go further and immediately issue a nationwide ban on ranitidine, saying, "FDA's failure to stop companies from selling ranitidine makes the United States government complicit in exposing infants and adults to the risk of cancer."

"Valisure's data, in combination with four decades of research, strongly suggests that ranitidine is a fundamentally unstable molecule and all products containing this drug have a risk of cancer," she wrote. "It is incomprehensible that the FDA is fully aware of this fact, yet, it continues to allow this product on the shelves."

More than a Contaminant

In its warning, the FDA called NDMA an "impurity," suggesting that ranitidine products were contaminated with the probable carcinogen. Valisure stated in a petition sent to the FDA that NDMA presence was not due to contamination, but was due to the nature of the ranitidine molecule.

They pointed out that the molecule itself contains the nitrate group and dimethylamine, which are the elements needed to form NDMA, and that the digestive process was likely a culprit for formation of the compound. They contend that the digestive process breaks down the chemical makeup of ranitidine and results in the formation of NDMA molecules.

Valisure supported this point by supplying data published by Stanford University that show a significant and disproportionate rise in the amount of MDMA excreted in urine following ranitidine ingestion.

Recalls Around the World

So far, 41 countries have taken more steps to protect consumers than the United States. In her letter, DeLauro noted that Bangladesh, Canada, Egypt, and South Korea have banned all sales of ranitidine because of concerns about MDMA. Germany, Denmark, Pakistan, Kenya, and Vietnam have removed ranitidine products from shelves and from their distribution channels.

Other countries have issued warnings about the dangers of ranitidine, while others have threatened to enforce fines upon sellers and distributors who fail to comply with recalls.

Zantac Lawsuits

Sanofi, which manufactures Zantac, is now facing lawsuits filed in courts across the United States, and a motion has been filed with the U.S. Judicial Panel on Multidistrict Litigation to consolidate many of the cases for pre-trial proceedings.

If you have used Zantac regularly and have been diagnosed with bladder, colon, kidney, rectal, stomach, or another cancer, you may be eligible to file a claim. Contact OnderLaw for a free consultation.

Call the Onder Law Firm at 314-963-9000, or click here to request a free consultation. The Onder Law Firm works on a contingency basis, meaning you pay us nothing unless you win your claim.

Tags for This Article:


More Recent Lawsuit News:

No-Cost, No-Obligation Case Review.

OnderLaw, LLC in St. Louis has developed a solid reputation of excellence as a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation, including Pradaxa, Lexapro and Yasmin/Yaz, Actos, Risperdal and others. The Onder Law Firm has won verdicts of more than $300 million in talcum powder ovarian cancer lawsuits, and has more experience representing Bayer/Monsanto glyphosate cancer victims than any other law firm in the country.

Free Case Review

Onder Law holds the highest possible peer review rating from Martindale-Hubbell

Onder Law holds the highest possible peer review rating from Martindale-Hubbell

Million Dollar Advocates Forum

We have been recognized by the Million Dollar Advocates Foum for securing million dollar settlements on behalf of our clients. Fewer than 1% of all attorneys receive this recgonition.

Multi-Million Dollar Advocates Forum

We have been recognized by the Million Dollar Advocates Foum for securing multi-million dollar settlements on behalf of our clients. Fewer than 1% of all attorneys receive this recgonition.

Super Lawyers

The attorneys of Onder Law have been recognized as Super Lawyers

Multi-Million Dollar Advocates Forum

We have been nominated as one of the Best Attorneys in America - The Most Qualified Attorneys in Our Country by Rue Ratings

Member National Trial Lawyers Association

The attorneys of Onder Law are proud members of the National Trial Lawyers Association

Onder Law handles mass tort claims that are filed in federal courts nationwide. Attorneys at Onder Law are licensed only in Missouri, Illinois and Kansas; however our attorneys have handled cases nationwide* including in: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.

Attorneys at Onder Law have represented clients in federal multi-district litigation in the following cities*: Atlanta, GA, Austin, TX, Baltimore, MD, Birmingham, AL, Boston, MA, Buffalo, NY, Charlotte, NC, Chicago, IL, Cincinnati, OH, Cleveland, OH, Columbus, OH, Dallas, TX, Denver, CO, Detroit, MI, Fresno, CA, Hartford, CT, Honolulu, HI, Houston, TX, Indianapolis, IN, Jacksonville, FL, Kansas City, MO, Las Vegas, NV, Los Angeles, CA, Louisville, KY, Memphis, TN, Miami, FL, Milwaukee, WI, Minneapolis, MN, Nashville, TN, New Orleans, LA, New York, NY, Oklahoma City, OK, Orlando, FL, Philadelphia, PA, Phoenix, AZ, Pittsburgh, PA, Portland, OR, Providence, RI, Raleigh, NC, Richmond, VA, Riverside, CA, Rochester, NY, Sacramento, CA, Salt Lake City, UT, San Antonio, TX, San Diego, CA San Francisco, CA, San Jose, CA, Seattle, WA, St. Louis, MO, Tampa, FL, Tucson, AZ, Tulsa, OK, Virginia Beach, VA and Washington, DC.

* In order to represent clients in states where the attorneys are not licensed, they must be granted admission pro hac vice or associate with local counsel.